Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.
01 1Aarti Pharmalabs
02 1Ami Organics Private Limited
03 1Beijing Cooperate Pharmaceutical Co. Ltd
04 1CTX Lifesciences
05 1Cangzhou Senary Chemical Science-tech Co., Ltd
06 1Glenfin Chemicals
07 1Guangzhou Topwork Chemical
08 1Indian Tex Dyes Industries
09 1Jinan Lead Pharmaceutical Technology
10 1Kimia Biosciences
11 1LifeFirst Pharma
12 2Nantong Chem-land
13 1Ningbo Syntame Biotech
14 1Royal Pharma
15 1SS Pharma
16 1Shanghai Jinli Biotechnology
17 1Smruthi Organics
18 1Speranza Chemical
19 1Srini Pharmaceuticals
20 1Synaptic Labs
21 1Xi'an Caijing Opto-Electrical Science & Technology
Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.
3-Morpholino-1-(4-(2-oxopiperidin-1-yl) phenyl) -5...
CAS Number : 545445-44-1
End Use API :
End Use API : Apixaban
About the Company : Aarti Pharmalab, earlier the pharma division of Aarti Industries, is a leading Indian manufacturer of APIs. It has dedicated facilities to manufacture HPAPIs, corticosteroids, cytotoxic...
3-MORPHOLINO-1-[4-(2-OXOPIPERIDIN-1-YL)PHENYL]-5,6...
CAS Number : 545445-44-1
End Use API :
End Use API : Apixaban
About the Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. is committed to meeting yo...
3-Morpholin-4-yl-1-[4-(2-oxopiperidin-1-yl)phenyl]...
CAS Number : 545445-44-1
End Use API :
End Use API : Apixaban
About the Company : Beijing Cooperate Pharmaceutical Co.,Ltd is a high-tech company specializing in pharmaceutical and advanced material, involving API,pharmaceutical intermediates and petrochemical additi...
5,6-dihydro-3-(4-morpholinyl)-1-(4-(2-oxo-1-piperi...
CAS Number : 545445-44-1
End Use API :
End Use API : Apixaban
About the Company : Founded in 2003, Senary Chem is one of the Key High-Tech Enterprises of National Torch Plan. Senary located in National Cangzhou Lingang Economic and Technological Development Zone,Cang...
3-Morpholino-1-(4-(2-oxopiperidin-1-yl)phenyl)-5,...
CAS Number : 545445-44-1
End Use API :
End Use API : Apixaban
About the Company : CTX is one of the youngest and fastest-growing Indian API and Intermediate manufacturing companies doing business in over 70 countries. In these five years, all my thoughts and actions ...
5,6-Dihydro-3-(4-morpholinyl)-1-[4-(2-oxo-1-piperi...
CAS Number : 545445-44-1
End Use API :
End Use API : Apixaban
About the Company : Glenfin Chemicals, a trusted provider of high-quality chemical solutions tailored to meet the diverse needs of industries worldwide. Based in the heart of innovation and excellence, we...
3-Morpholino-1-(4-(2-oxopiperidin-1-yl)phenyl)-5,6...
CAS Number : 545445-44-1
End Use API :
End Use API : Apixaban
About the Company : Guangzhou Topwork Chemical Co., Ltd. Specializes in manufacturing corticosteroid and relative intermediates. We provide high quality products and excellent service to our clients and ha...
3-morpholino-1-(4-(2-oxopiperidin-1-yl) phenyl)-5,...
CAS Number : 545445-44-1
End Use API :
End Use API : Apixaban
About the Company : TEXLAB INDUSTRIES was established in 1971, manufacturing & trading related business. TEXLAB INDUSTRIES - company launched by Late Shree AMBALAL MISTRY for local and global region with t...
5,6-Dihydro-3-(4-morpholinyl)-1-[4-(2-oxo-1-piperi...
CAS Number : CAS-545445-44-1
End Use API :
End Use API : Apixaban
About the Company : Jinan Lead Pharmaceutical Technology Co., LTD., located in Jinan, Shandong Province, is mainly engaged in R&D, production and sales of pharmaceutical raw materials and intermediates. Th...
5,6-Dihydro-3-(4-morpholinyl)-1-[4-(2-oxo-1-piperi...
CAS Number : 545445-44-1
End Use API :
End Use API : Apixaban
About the Company : Kimia Biosciences, established in 1993, is focused on manufacturing bulk drugs for various therapeutic segments. With a strong emphasis on excellence and advanced technologies, Kimia ai...
